-+ 0.00%
-+ 0.00%
-+ 0.00%

Citizens Reiterates Market Outperform on CRISPR Therapeutics, Maintains $80 Price Target

Benzinga·07/06/2026 12:42:29
Listen to the news
Citizens analyst Silvan Turkcan reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Market Outperform and maintains $80 price target.